196 related articles for article (PubMed ID: 2409659)
1. Approaches to cancer therapy using biological response modifiers.
MacEwen EG
Vet Clin North Am Small Anim Pract; 1985 May; 15(3):667-88. PubMed ID: 2409659
[No Abstract] [Full Text] [Related]
2. Comparative aspects of cancer immunotherapy: immunologic methods used for treatment of spontaneous cancer in animals.
Theilen GH; Hills D
J Am Vet Med Assoc; 1982 Nov; 181(10):1134-41. PubMed ID: 6757216
[No Abstract] [Full Text] [Related]
3. Biological response modifiers: their potential and limitations in cancer therapeutics.
Mihich E
Cancer Invest; 1985; 3(1):71-83. PubMed ID: 2578860
[No Abstract] [Full Text] [Related]
4. Future perspectives for biological response modifiers: a viewpoint.
Mihich E
Semin Oncol; 1986 Jun; 13(2):234-54. PubMed ID: 2424090
[No Abstract] [Full Text] [Related]
5. [Immunity against cancer--a critical review of recent progress--].
Yamamura Y
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt 2):311-9. PubMed ID: 6192758
[TBL] [Abstract][Full Text] [Related]
6. Biological response modifiers: preclinical evaluation and clinical activity.
Smalley RV; Oldham RK
Crit Rev Oncol Hematol; 1984; 1(3):259-94. PubMed ID: 6085037
[TBL] [Abstract][Full Text] [Related]
7. An immunologic approach to the treatment of cancer.
MacEwen EG
Vet Clin North Am; 1977 Feb; 7(1):65-75. PubMed ID: 191975
[No Abstract] [Full Text] [Related]
8. Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells.
Koff WC; Fidler IJ; Showalter SD; Chakrabarty MK; Hampar B; Ceccorulli LM; Kleinerman ES
Science; 1984 Jun; 224(4652):1007-9. PubMed ID: 6426057
[TBL] [Abstract][Full Text] [Related]
9. [The principles in correcting secondary immunodeficiencies by using 2 immunomodulators of differing character--purified staphylococcal anatoxin and likopid].
Semenova IB
Zh Mikrobiol Epidemiol Immunobiol; 1998; (1):100-4. PubMed ID: 9532703
[No Abstract] [Full Text] [Related]
10. Chemically defined immunotherapeutic agents.
Hadden JW
Prog Clin Biol Res; 1983; 132E():273-86. PubMed ID: 6196787
[No Abstract] [Full Text] [Related]
11. Biologic response modifiers: the future of cancer therapy?
MacEwen EG
Vet Clin North Am Small Anim Pract; 1990 Jul; 20(4):1055-73. PubMed ID: 2196730
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy.
Bergman PJ
Vet Clin North Am Small Anim Pract; 2010 May; 40(3):507-18. PubMed ID: 20471533
[TBL] [Abstract][Full Text] [Related]
13. Cancer Immunotherapies.
Bergman PJ
Vet Clin North Am Small Anim Pract; 2019 Sep; 49(5):881-902. PubMed ID: 31186125
[TBL] [Abstract][Full Text] [Related]
14. Planning cancer therapy.
MacEwen EG
Vet Clin North Am; 1977 Feb; 7(1):3-11. PubMed ID: 850987
[No Abstract] [Full Text] [Related]
15. Biological response modifiers.
Clark JW
Cancer Chemother Biol Response Modif; 1991; 12():193-212. PubMed ID: 1931443
[No Abstract] [Full Text] [Related]
16. Biologicals and biological response modifiers: fourth modality of cancer treatment.
Oldham RK
Cancer Treat Rep; 1984 Jan; 68(1):221-32. PubMed ID: 6198081
[TBL] [Abstract][Full Text] [Related]
17. Biologicals and biological response modifiers: new approaches to cancer treatment.
Oldham RK
Cancer Invest; 1985; 3(1):53-70. PubMed ID: 3918773
[No Abstract] [Full Text] [Related]
18. Recent developments in immunomodulatory therapy.
Bardana EJ
J Allergy Clin Immunol; 1985 Apr; 75(4):423-40. PubMed ID: 2579994
[No Abstract] [Full Text] [Related]
19. [Proliferating ability of the lymphocytes of demodectic dogs during immune cell-stimulating therapy].
Kraiss A
Tierarztl Prax; 1987; 15(1):63-6. PubMed ID: 3590169
[TBL] [Abstract][Full Text] [Related]
20. [Immunostimulants--therapeutic aspects].
Diezel W; Volk HD; Daniel V; Gruner S; Sönnichsen N
Arch Geschwulstforsch; 1989; 59(1):45-51. PubMed ID: 2493778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
